Compare ANIP & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIP | ATEC |
|---|---|---|
| Founded | 2001 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1999 | 2006 |
| Metric | ANIP | ATEC |
|---|---|---|
| Price | $74.40 | $12.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $107.33 | $22.36 |
| AVG Volume (30 Days) | 324.0K | ★ 2.3M |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 419.23 | 15.04 |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $206,547,000.00 | $101,739,000.00 |
| Revenue This Year | $19.88 | $17.79 |
| Revenue Next Year | $15.77 | $16.43 |
| P/E Ratio | $22.77 | ★ N/A |
| Revenue Growth | ★ 2.47 | N/A |
| 52 Week Low | $56.71 | $8.82 |
| 52 Week High | $99.50 | $23.29 |
| Indicator | ANIP | ATEC |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 27.69 |
| Support Level | $62.89 | $11.99 |
| Resistance Level | $85.12 | $12.90 |
| Average True Range (ATR) | 2.65 | 0.63 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 23.01 | 5.61 |
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.